Orchid Pharma Ltd (ORCHPHARMA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Supriya Lifesci.

Guj. Themis Bio.

Senores Pharma.

Aarti Drugs

Sequent Scien.

RPG LifeScience.

Dishman Carbogen

Innova Captab

Zota Health Care

Orchid Pharma

SPARC

Why is Orchid Pharma Ltd ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 11.87% and Operating profit at 18.41% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.91

With a fall in Net Sales of -8.98%, the company declared Very Negative results in Sep 25

The company has declared negative results for the last 4 consecutive quarters
The company has declared negative results in Dec 24 after 2 consecutive negative quarters
PAT(Q) At Rs -5.72 cr has Fallen at -126.8% (vs previous 4Q average)
ROCE(HY) Lowest at 4.28%
OPERATING PROFIT TO INTEREST (Q) Lowest at -0.40 times

With ROCE of 2.3, it has a Very Expensive valuation with a 3.2 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -49.08%, its profits have fallen by -56.1%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Orchid Pharma for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Orchid Pharma

-48.93%

-1.02

47.89%

Sensex

4.83%

0.41

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.87%

EBIT Growth (5y)

18.41%

EBIT to Interest (avg)

1.91

Debt to EBITDA (avg)

5.83

Net Debt to Equity (avg)

0.10

Sales to Capital Employed (avg)

0.55

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.60%

ROCE (avg)

0.90%

ROE (avg)

4.62%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.44

EV to EBIT

141.28

EV to EBITDA

67.45

EV to Capital Employed

3.21

EV to Sales

5.50

PEG Ratio

Dividend Yield

ROCE (Latest)

2.27%

ROE (Latest)

4.10%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-29What is not working for the Company

PAT(Q)

At Rs -5.72 cr has Fallen at -126.8% (vs previous 4Q average

ROCE(HY)

Lowest at 4.28%

OPERATING PROFIT TO INTEREST (Q)

Lowest at -0.40 times

OPERATING PROFIT TO NET SALES(Q)

Lowest at -0.76%

DEBT-EQUITY RATIO(HY)

Highest at 0.22 times

NET SALES(Q)

At Rs 193.52 cr has Fallen at -9.0% (vs previous 4Q average

PBDIT(Q)

Lowest at Rs -1.48 cr.

PBT LESS OI(Q)

Lowest at Rs -14.10 cr.

EPS(Q)

Lowest at Rs -1.13

Loading Valuation Snapshot...

Here's what is not working for Orchid Pharma

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs -14.10 cr has Fallen at -213.3% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 12.45 Cr

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs -5.72 cr has Fallen at -126.8% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 21.31 Cr

MOJO Watch

Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit to Interest - Quarterly

Lowest at -0.40 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit Margin - Quarterly

Lowest at -0.76% and Fallen

each quarter in the last five quarters

MOJO Watch

Company's efficiency has deteriorated

Operating Profit to Sales

Net Sales - Quarterly

At Rs 193.52 cr has Fallen at -9.0% (vs previous 4Q average)

over average Net Sales of the previous four quarters of Rs 212.61 Cr

MOJO Watch

Near term sales trend is negative

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly

Lowest at Rs -1.48 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

Lowest at Rs -14.10 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly

Lowest at Rs -1.13

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)

Debt-Equity Ratio - Half Yearly

Highest at 0.22 times

in the last five half yearly periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio